GlassScriptPhysician profile
Dushan Majkic
NPI 1396775516
$20,448.17
in general payments reported to CMS, 2019-2025
45 companies · $3,100 in 2025
The $3,100 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,219 · 2020: $2,498 · 2021: $3,001 · 2022: $3,127 · 2023: $3,314 · 2024: $3,188 · 2025: $3,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,571 · Education: $31.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,570.88 |
| Education | $31.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,747.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $2,110.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $2,035.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,963.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,716.64 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,624.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $1,475.08 | 2019-2025 | Spravato, Xarelto |
| Abbvie INC. | $988.60 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $747.66 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Sanofi-Aventis U.S. LLC | $666.99 | 2019-2023 | |
| Amgen INC. | $530.83 | 2019-2025 | Otezla, Repatha, Repatha |
| Edwards Lifesciences Corporation | $508.39 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $374.53 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $363.54 | 2019-2025 | Camzyos, Eliquis |
| Phathom Pharmaceuticals, INC. | $342.98 | 2024-2025 | Voquezna |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.65 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $245.49 | 2022-2025 | Freestyle Libre 3 |
| Pulmonx Corporation | $198.87 | 2024-2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Esperion Therapeutics, INC. | $167.27 | 2020-2021 | |
| Astellas Pharma US INC | $135.14 | 2019-2025 | Veozah |
| Dexcom, INC. | $131.71 | 2021-2025 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $111.37 | 2019-2020 | |
| Exact Sciences Corporation | $111.02 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $98.38 | 2020 | |
| Seqirus USA INC | $80.39 | 2024-2025 | Fluad, Flucelvax |
| Eisai INC. | $75.42 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $72.85 | 2021-2022 | |
| Sanofi Pasteur INC. | $57.96 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $56.81 | 2019 | |
| Radius Health, INC. | $50.11 | 2023-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $47.46 | 2019 | |
| Ardelyx, INC. | $36.24 | 2024 | Ibsrela |
| Biohaven Pharmaceutical Holding Company LTD. | $33.50 | 2022 | |
| Horizon Therapeutics Plc | $33.07 | 2019 | |
| Verona Pharma, INC. | $32.64 | 2025 | Ohtuvayre |
| Idorsia Pharmaceuticals US INC | $32.03 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $28.19 | 2022-2025 | Zoryve |
| Amarin Pharma, INC. | $22.72 | 2021 | |
| Inspire Medical Systems, INC. | $20.74 | 2025 | Inspire |
| Phadia US INC. | $19.75 | 2025 | Immunocap |
| Sumitomo Pharma America, INC. | $17.61 | 2024 | Gemtesa |
| Theracosbio, LLC | $16.33 | 2024 | Brenzavvy |
| Acella Pharmaceuticals, LLC | $15.87 | 2025 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $14.69 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.81 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dushan Majkic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.